Procalcitonin values after dialysis is closely related to type of dialysis membrane

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 6, 2009, Pages 703-707

  Montagnana, Martina ^a   Lippi, Giuseppe ^a   Tessitore, Nicola ^b   Salvagno, Gian Luca ^a   Danese, Elisa ^a   Targher, Giovanni ^c   Lupo, Antonio ^b   Guidi, Gian ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b Dipartimento di Scienze Biomediche e Chirurgiche   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Chronic renal failure; CRP; Haemodialysis; Membrane; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DIALYSIS MEMBRANE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DYSFUNCTION; MALE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

AGED; C-REACTIVE PROTEIN; CALCITONIN; FEMALE; HUMANS; MALE; MEMBRANES, ARTIFICIAL; PROTEIN PRECURSORS; RENAL DIALYSIS; STATISTICS, NONPARAMETRIC;

BACTERIA (MICROORGANISMS);

EID: 72949111830     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365510902993663     Document Type: Article

References (31)

1. Khan IN, C atto GRD. L ong-term complications of dialysis: infection. Kidney Int. 1993;43:143-148
2. Katneni R, Hedayati SS. Central venous catheter-related bacteremia in chronic hemodialysis patients: epidemiology and evidence-based management. Nat Clin Pract Nephrol. 2007;3:256-266
3. Eleftheriadis T, A ntoniadi G, L iakopoulos V, K artsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial. 2007;20:440-451
4. Rangel MC, C oronado VG, E uler GL, Strikas RA. V accine recommendations for patients on chronic dialysis. Semin Dial. 2000;13:101-107
5. Herget-Rosenthal S, M arggraf G, P ietruck F, H using J, Strupat M, Philipp T, Kribben A. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant. 2001;16:975-979
6. Zimmermann J, H errlinger S, P ruy A, Metzger T, Wanner C. Infl ammation enhances cardiovascular risk and mortality in hemodialysis. Kidney Int. 1999;55:648-658
7. Haverkate F, T hompson SG, P ype SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466
8. Schneider HG, Lam QT. P rocalcitonin for the clinical laboratory: a review. Pathology. 2007;39:383-390
9. Simon L, G auvin F, A mre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206-217
10. Dandona P, N ix D, Wilson MF, Aljada A, L ove J, Assicot M, Bohuon C. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79:1605-1608
11. Nylen ES, Whang KT, S nider RH, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998;26:1001-1006
12. Herbelin A, Nguyen AT, Zingraff J, Urena P, Deschamps-Latscha B. Infl uence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor. Kidney Int. 1990;37:116-125
13. Herbelin A, U rena P, N guyen AT, Z ingraff J, D eschamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991;39:954-960
14. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49:S57-61.
15. Carrol ED, Thomson AP, H art CA. P rocalcitonin as a marker of sepsis. Int J Antimicrob Agents. 2002;20:1-9.
16. Meisner M, T schaikowsky K, P almaers T, Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care. 1999;3:45-50.
17. Boeken U, Feindt P, Micek M, Petzold T, S chulte HD, Gams E. Procalcitonin in cardiac surgery: diagnostic value in systemic infl ammatory response syndrome (SIRS), sepsis and after heart transplantation. Cardiovasc Surg. 2000;8:550-554
18. Schuttrumpf S, B inder L, H agemann T, B erkovic D, T rumper L, Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol. 2003;82:98-103.
19. Panichi V, R izza GM, P aoletti S, B igazzi R, A loisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R. RISCAVID Study Group. Chronic infl ammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study. Nephrol Dial Transplant. 2008;23:2337-2343
20. Kim BS, Jeon DS, Shin MJ, Kim YO, S ong HC, Lee SH, Kim SY, Choi EJ, Chang YS, Bang BK. Persistent elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol. 2005;25:189-195
21. Hengst JM. T he role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care. 2003;3:3-13.
22. Ugarte H, Silva E, M ercan D, D e Mendonca A, V incent JL. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med. 1999;27:498-504.
23. Peres Bota D, Melot C, L opes Ferreira F, V incent JL. Infection Probability Score (IPS): a method to help assess the probability of infection in critically ill patients. Crit Care Med. 2003;31:2579-2584
24. Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. C-reactive protein as a marker of ventilator- associated pneumonia resolution - a pilot study. Eur Respir J. 2005;25:804-812
25. Prat C, S ancho JM, D ominguez J, X icoy B, G imenez M, Ferra C, Blanco S, Lacoma A, Ribera JM, Ausina V. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49:1752-1761
26. Conti G, Amore A, Chiesa M, M ancuso D, Cirina P, Mengozzi G, Santoro A, Coppo R. Procalcitonin as a marker of micro-infl ammation in hemodialysis. J Nephrol. 2005;18:282-288
27. Rinaldi S, Adembri C, Grechi S, De Gaudio AR. Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med. 2006;34:2334-2339
28. Nobre V, H arbarth S, G raf JD, R ohner P, P ugin J. U se of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177:498-505.
29. Vanholder R, Schepers E, Meert N, Lameire N. W hat is uremia? Retention vs. oxidation. Blood Purif. 2006;24:33-38
30. Galli F. Protein damage and infl ammation in uraemia and dialysis patients. Nephrol Dial Transplant. 2007;22(Suppl. 5) : v20-36.
31. Ooi DS, H ouse AA. Cardiac troponin T in hemodialyzed patients. Clin Chem. 1998;44:1410-1416